Refine
Year of publication
Document Type
- Article (29947)
- Part of Periodical (11831)
- Book (8221)
- Doctoral Thesis (5587)
- Part of a Book (3622)
- Working Paper (3370)
- Review (2860)
- Contribution to a Periodical (2278)
- Preprint (1805)
- Report (1545)
Language
- German (41978)
- English (28346)
- French (1067)
- Portuguese (722)
- Multiple languages (306)
- Croatian (302)
- Spanish (301)
- Italian (194)
- mis (174)
- Turkish (148)
Is part of the Bibliography
- no (73863) (remove)
Keywords
- Deutsch (1037)
- Literatur (798)
- taxonomy (737)
- Deutschland (541)
- Rezension (491)
- new species (438)
- Frankfurt <Main> / Universität (341)
- Rezeption (320)
- Geschichte (291)
- Linguistik (268)
Institute
- Medizin (7361)
- Präsidium (5082)
- Physik (4113)
- Extern (2661)
- Wirtschaftswissenschaften (2657)
- Gesellschaftswissenschaften (2366)
- Biowissenschaften (2110)
- Biochemie und Chemie (1949)
- Center for Financial Studies (CFS) (1609)
- Informatik (1576)
The remains of the ancient Roman town, crossed by the Flaminia road and lapped by a bend of the Tiber, are located in a natural landscape of significant beauty, perfect synthesis of archaeology and nature that remained unchanged throughout centuries. Excavations were conducted here from a very early period, especially from 1776 to 1784, when a great quantity of material was removed. The archaeological excavations carried out in Otricoli in the second half of the Seventeenth century together with discoveries in Herculaneum, Pompeii, Stabiae and other cities of ancient Italy, contributed during the Neoclassical period to the rediscovery of classical ideals in art and architecture, partly already rediscovered during Humanism and the Renaissance in Italy.
Die vorliegende Studie beschäftigt sich mit der Konstituierung von amicitia im Mythos und fragt nach der Erzählung als Gabe im amikalen Gabentauschzyklus. Die Hinweise auf amicitia als eine der zentralen Bindungstypen des römischen Gemeinwesens sind über verschiedene Werke verstreut, lassen aber bereits die Wirkkraft erahnen, weil sie rückblickend in die Frühzeit hineingeschrieben wurden. In diesem Zusammenhang wird auch die Bedeutung der Erzählung als Gabe im Gabentauschzyklus untersucht, da diese die Transformation vom Fremden zum Anderen ermöglichen kann; erst auf diese Weise wird eine Grundlage für amicitia geschaffen. Darüber hinaus gelingt erst in der Urvergangenheit des Mythos’ die Perpetuierung von amicitia und dem sie konstituierenden amikalen Gabentausch.
Endogenous nitro-fatty acids (NFA) are potent electrophilic lipid mediators that exert biological effects in vitro and in vivo via selective covalent modification of thiol-containing target proteins. The cytoprotective, anti-inflammatory, and anti-tumorigenic effects of NFA in animal models of disease caused by targeted protein nitroalkylation are a valuable basis for the development of future anti-phlogistic and anti-neoplastic drugs. Considering the complexity of diseases and accompanying comorbidities there is an urgent need for clinically effective multifunctional drugs. NFA are composed of a fatty acid backbone containing a nitroalkene moiety triggering Michael addition reactions. However, less is known about the target-specific structure–activity relationships and selectivities comparing different NFA targets. Therefore, we analyzed 15 NFA derivatives and compared them with the lead structure 9-nitro-oleic acid (9NOA) in terms of their effect on NF-κB (nuclear factor kappa B) signaling inhibition, induction of Nrf-2 (nuclear factor erythroid 2-related factor 2) gene expression, sEH (soluble epoxide hydrolase), LO (lipoxygenase), and COX-2 (cyclooxygenase-2) inhibition, and their cytotoxic effects on colorectal cancer cells. Minor modifications of the Michael acceptor position and variation of the chain length led to drugs showing increased target preference or enhanced multi-targeting, partly with higher potency than 9NOA. This study is a significant step forward to better understanding the biology of NFA and their enormous potential as scaffolds for designing future anti-inflammatory drugs.
The complex and adaptive nature of malignant neoplasm constitute a major challenge for the development of effective anti-oncogenic therapies. Emerging evidence has uncovered the pivotal functions exerted by the small leucine-rich proteoglycans, decorin and biglycan, in affecting tumor growth and progression. In their soluble forms, decorin and biglycan act as powerful signaling molecules. By receptor-mediated signal transduction, both proteoglycans modulate key processes vital for tumor initiation and progression, such as autophagy, inflammation, cell-cycle, apoptosis, and angiogenesis. Despite of their structural homology, these two proteoglycans interact with distinct cell surface receptors and thus modulate distinct signaling pathways that ultimately affect cancer development. In this review, we summarize growing evidence for the complex roles of decorin and biglycan signaling in tumor biology and address potential novel therapeutic implications.
Effect of chemotherapy on overall survival in contemporary metastatic prostate cancer patients
(2021)
Introduction: Randomized clinical trials demonstrated improved overall survival in chemotherapy exposed metastatic prostate cancer patients. However, real-world data validating this effect with large scale epidemiological data sets are scarce and might not agree with trials. We tested this hypothesis.
Materials and Methods: We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results (SEER) database (2014-2015). Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed patients vs chemotherapy-naïve patients. All analyses were repeated in propensity-score matched cohorts. Additionally, landmark analyses were applied to account for potential immortal time bias.
Results: Overall, 4295 de novo metastatic prostate cancer patients were identified. Of those, 905 (21.1%) patients received chemotherapy vs 3390 (78.9%) did not. Median overall survival was not reached at 30 months follow-up. Chemotherapy-exposed patients exhibited significantly better overall survival (61.6 vs 54.3%, multivariable HR:0.82, CI: 0.72-0.96, p=0.01) at 30 months compared to their chemotherapy-naïve counterparts. These findings were confirmed in propensity score matched analyses (multivariable HR: 0.77, CI:0.66-0.90, p<0.001). Results remained unchanged after landmark analyses were applied in propensity score matched population.
Conclusions: In this contemporary real-world population-based cohort, chemotherapy for metastatic prostate cancer patients was associated with better overall survival. However, the magnitude of overall survival benefit was not comparable to phase 3 trials.
Introduction: To evaluate the oncological outcome of high dose rate (HDR) brachytherapy (BRT) as monotherapy for clinically localised prostate cancer (PCA).
Material and Methods: Between January 2002 and February 2004, 141 consecutive patients with clinically localised PCA were treated with HDR-BRT monotherapy. The cohort comprised 103 (73%) low-, 32 (22.7%) intermediate- and 6 (4.3%) high risk patients according to D’Amico classification or 104 (73.8%) low-, 24 (17.0%) intermediate favourable-, 12 (8.5%) intermediate unfavourable- and one (0.7%) very high risk patient according to National Comprehensive Cancer Network (NCCN) one. Patients received four fractions of 9.5 Gy delivered within a single implant up to a total physical dose of 38 Gy. Catheter-implantation was transrectal ultrasound-based whereas treatment planning CT-based. Thirty-three patients (23.4%) received ADT neoadjuvantly and continued concurrently with BRT. Biochemical relapse-free survival (BRFS) was defined according to the Phoenix Consensus Criteria and genitourinary (GU)/gastrointestinal (GI) toxicity evaluated using the Common Toxicity Criteria for Adverse Events version 5.0.
Results: Median age at treatment and median follow-up time was 67.2 and 15.2 years, respectively. Twenty-three (16.3%) patients experienced a biochemical relapse and 5 (3.5%) developed distant metastases, with only one patient dying of PCA. The BRFS was 85.1% at 15 years and 78.7% at 18 years. The corresponding overall survival, metastases-free survival, and prostate cancer specific mortality at 15- and 18-years was 73.9%/59.1%, 98.3%/90.6%, and 100%/98.5% respectively. Late grade 3 GI and GU toxicity was 4.2% and 5.6% respectively. Erectile dysfunction grade 3 was reported by 27 (19%) patients. From the prognostic factors evaluated, tumor stage (≤T2b compared to ≥T2c) along with the risk group (low-intermediate vs. high) when using the D’Amico classification but not when the NCCN one was taken into account, correlated significantly with BRFS.
Conclusion: Our long-term results confirm HDR-BRT to be a safe and effective monotherapeutic treatment modality for low- and intermediate risk PCA.